Physician profile
Sandra Estrada
NPI 1427082833
$12,471.31
in general payments reported to CMS, 2019-2025
57 companies · $2,835 in 2025
The $2,835 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,783 · 2022: $2,114 · 2023: $3,890 · 2024: $1,848 · 2025: $2,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,369 · Travel and Lodging: $1,105 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,369.41 |
| Travel and Lodging | $1,104.50 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,673.09 | 2021-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $667.52 | 2021-2025 | |
| Emd Serono, INC. | $658.88 | 2022-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $643.34 | 2021-2025 | |
| Lilly USA, LLC | $484.86 | 2021-2025 | Reyvow, Emgality, Kisunla |
| Pfizer INC. | $481.59 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $440.48 | 2021-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $421.23 | 2022-2025 | |
| Merz Pharmaceuticals, LLC | $341.42 | 2022-2025 | Xeomin, Inbrija |
| Tg Therapeutics, INC. | $330.62 | 2023-2025 | |
| Sk Life Science, INC. | $287.42 | 2021-2025 | |
| Impel Pharmaceuticals INC. | $282.44 | 2022-2023 | Trudhesa |
| Neurelis, INC. | $279.46 | 2023-2025 | Valtoco |
| Argenx US, INC. | $269.37 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $257.89 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $257.37 | 2021-2025 | Rystiggo, Briviact, Zilbrysq |
| Genentech USA, INC. | $243.64 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Lundbeck LLC | $229.50 | 2023-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $226.65 | 2022-2025 | Nuplazid |
| Acorda Therapeutics, INC | $207.11 | 2021-2024 | Inbrija, Ampyra |
| Amgen INC. | $204.02 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $191.11 | 2022 | |
| Celgene Corporation | $188.47 | 2022-2025 | Zeposia |
| Janssen Biotech, INC. | $181.52 | 2025 | |
| Sumitomo Pharma America, INC. | $161.28 | 2023-2024 | Aptiom |
| Biogen, INC. | $159.47 | 2021-2025 | Vumerity, Tysabri |
| Alnylam Pharmaceuticals INC. | $138.44 | 2023-2025 | Onpattro, Amvuttra |
| Csl Behring | $138.39 | 2021-2025 | Hizentra |
| Eisai INC. | $136.88 | 2023-2025 | |
| Upsher-Smith Laboratories LLC | $119.86 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $102.43 | 2021-2025 | Rytary, Crexont |
| Biohaven Pharmaceutical Holding Company LTD. | $99.90 | 2022 | |
| Neurocrine Biosciences, INC. | $83.31 | 2022-2024 | Ingrezza, Ongentys |
| Jazz Pharmaceuticals INC. | $73.77 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.21 | 2025 | Hyqvia |
| Azurity Pharmaceuticals, INC. | $62.98 | 2023-2024 | Horizant, Horizant |
| Boston Scientific Corporation | $57.64 | 2024 | |
| Sunovion Pharmaceuticals INC. | $56.60 | 2021-2022 | |
| Avion Pharmaceuticals | $52.72 | 2022 | |
| Ge Healthcare | $49.66 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $48.27 | 2023-2024 | Rexulti, Nuedexta |
| Biohaven Pharmaceuticals, INC. | $44.53 | 2021 | |
| Collegium Pharmaceutical, INC. | $37.91 | 2025 | Jornay Pm |
| Kyowa Kirin, INC. | $34.35 | 2022-2023 | Crysvita |
| Avanir Pharmaceuticals, INC. | $33.78 | 2021-2022 | |
| Amylyx Pharmaceuticals, INC. | $31.07 | 2023 | Relyvrio |
| Currax Pharmaceuticals LLC | $29.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.64 | 2021 | |
| Corium, LLC | $22.92 | 2023 | Adlarity |
| Cala Health, INC. | $22.51 | 2023 | Cala Trio |
| Astrazeneca Pharmaceuticals LP | $20.09 | 2025 | |
| Banner Life Sciences, LLC | $19.97 | 2023 | |
| Horizon Therapeutics Plc | $18.90 | 2023 | Uplizna |
| Mdd US Operations, LLC | $18.90 | 2021 | |
| Octapharma USA, INC. | $18.88 | 2022 | |
| Itf Therapeutics LLC | $18.68 | 2024 | |
| Allergan, INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Estrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.